April 30, 2018 09:57 AM EDT
R&D

Al­ler­gan's $639M Vi­tae buy­out is a bust. R&D writes off their pso­ri­a­sis pro­gram as a com­plete loss

John Carroll

Editor & Founder

Al­ler­gan’s $639 mil­lion buy­out of Vi­tae is a bust.

The bio­phar­ma group $AGN re­port­ed this morn­ing that it is writ­ing off the Phase II …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Cas­es of se­vere RSV in two Mod­er­na vac­cine can­di­dates' tri­als raise ques­tions about fu­ture

Ex­clu­sive: Two Vi­da Ven­tures co-founders ex­it the VC firm

Ear­ly da­ta on BTK de­graders sug­gest promise of next-gen ap­proach

J&J, Leg­end’s Carvyk­ti clears a type of blood can­cer in ‘nine out of 10’ pa­tients

Roche ini­tial­ly did­n't want to buy Po­sei­da — and part­ner Astel­las did­n't sub­mit an of­fer, new fil­ings show

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times